Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

NCT06207734 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Continuation of CDK4/6 inhibitor Palbociclib
DRUG: Discontinuation of CDK4/6 inhibitor Palbociclib
DRUG: Continuation of CDK4/6 inhibitor -Palbociclib
DRUG: Discontinuation of CDK4/6 inhibitor -Palbociclib
DRUG: Continuation of CDK4/6 inhibitor Abemaciclib
DRUG: Discontinuation of CDK4/6 inhibitor Abemaciclib

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest